Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy
Open Access
- 4 June 2020
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (7), 1857-1866
- https://doi.org/10.3324/haematol.2020.251371
Abstract
Despite several therapeutic advances, patients with multiple myeloma (MM) require additional treatment options since no curative therapy exists yet. In search of a novel therapeutic antibody, we previously applied phage display with myeloma cell screening and developed TP15, a scFv targeting intercellular adhesion molecule 1 (ICAM-1/CD54). To more precisely evaluate the antibody's modes of action, fully human IgG1 antibody variants were generated bearing wild-type (MSH-TP15) or mutated Fc to either enhance (MSH-TP15 Fc-eng.) or prevent (MSH-TP15 Fc k.o.) Fc gamma receptor binding. Especially MSH-TP15 Fc-eng. induced potent antibody-dependent cell-mediated cytotoxicity (ADCC) against malignant plasma cells by efficiently recruiting NK cells and engaged macrophages for antibody-dependent cellular phagocytosis (ADCP) of tumor cells. Binding studies with truncated ICAM-1 demonstrated MSH-TP15 binding to ICAM-1 domain 1-2. Importantly, MSH-TP15 and MSH-TP15 Fc-eng. both prevented myeloma cell engraftment and significantly prolonged survival of mice in an intraperitoneal xenograft model. In the subcutaneous model MSH-TP15 Fc-eng. was superior to MSH-TP15, whereas MSH-TP15 Fc k.o. was not effective in both models - reflecting the importance of Fc-dependent mechanisms of action also in vivo. The efficient recruitment of immune cells and the potent anti-tumor activity of the Fc-engineered MSH-TP15 antibody hold significant potential for myeloma immunotherapy.Keywords
This publication has 48 references indexed in Scilit:
- PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myelomaLeukemia, 2012
- Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cellsMolecular Cancer, 2010
- Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functionsmAbs, 2010
- Rapid induction of apoptosis in B‐cell lymphoma by functionally isolated human antibodiesInternational Journal of Cancer, 2006
- Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapyThe Journal of Experimental Medicine, 2006
- Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytomaThe Hematology Journal, 2001
- Repeat treatment of Rheumatoid Arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibodyArthritis & Rheumatism, 1997
- Expression of Adhesion Molecules on Myeloma CellsJapanese Journal of Cancer Research, 1996
- A PHASE I TRIAL OF IMMUNOSUPPRESSION WITH ANTIIC AM-1 (CD54) mAb IN RENAL ALLOGRAFT RECIPIENTSTransplantation, 1993
- Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cellsBritish Journal of Haematology, 1991